Navigation Links
Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study of HGS-ETR1 -

ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today reported that clinical and preclinical evidence continues to emerge demonstrating that its TRAIL receptor antibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), have significant potential for use in the treatment of a broad range of cancers.

"We believe that HGS-ETR1 and HGS-ETR2 could offer novel, highly targeted therapeutic options that may prove useful in the treatment of a number of cancers," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGS. "We note with pride that the Journal of Clinical Oncology, one of the field's most prestigious peer-reviewed publications, chose to publish the first human study of HGS-ETR1 earlier this month with an accompanying editorial - and, last week at AACR 2007, approximately 1500 cancer scientists and researchers attended our oral presentation of research results to date."

Results in the Journal of Clinical Oncology

The results of the first Phase 1 clinical trial of mapatumumab (HGS-ETR1) appeared in the April 10 issue of the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology (ASCO). These results in 49 patients demonstrated that mapatumumab could be administered safely and repetitively to patients with advanced solid malignancies. The authors concluded that the absence of severe toxicities, and mapatumumab's ability to achieve blood levels consistent with antitumor activity in laboratory models, warrant further study of mapatumumab as a single agent and in combination with chemotherapy in a broad array of tumors.

Based on the initial Phase 1 results, along with extensive preclinical data, HGS initiated a broad clinical development program that included Phase 2 trials of HGS-ETR1 as a sin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

Post Your Comments:
(Date:11/19/2009)..., , TAINAN, Taiwan, Nov. 19 /PRNewswi...of active pharmaceutical ingredients (APIs), annou...ent Compound Safety Certification from,SafeBridge(...inoPharm,s,competency and proficiency in the safe ...ts (APIs), and applies to specific laboratories an...
(Date:11/19/2009)..., , CAMBRIDGE, Mass., Nov. 19 /PRNewswire... small molecule microarray technology to find drug... it has raised $1M in seed financing led by incTAN...mplete its initial discovery campaign that will sc...With this investment, incTANK Ventures General Par...
(Date:11/19/2009)..., , NEWPORT NEWS, Va., Nov. 19 /PRNewswire/... Imaging (BSGI/MBI) has been recognized and endors...ght against breast cancer: The Society of Breast I... Both societies published articles supporting the ...echnology for the early detection of breast cancer...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3Drinking Your Way to Health 3F Perhaps Not 59700 1Drinking Your Way to Health 3F Perhaps Not 59700 2Drinking Your Way to Health 3F Perhaps Not 59700 3A new understanding of why seizures occur with alcohol withdrawal 59697 1Post Traumatic Stress May Raise Death Risks 59693 1Post Traumatic Stress May Raise Death Risks 59693 2
... -Biologics License Application for Wrinkles/Nasol... Two Weeks- , , , EXTON, Pa., March 5 Isolagen(...top-line efficacy results from a Phase II/III clin...y(TM) for the treatment of moderate to severe acne...ts and was statistically significant, making this ...
... mTBI Accident , , Presentation at American Balan...eturning Vets , , PITTSBURGH, March 4 With recor... and Afghanistan with brain injuries, a case study...ics.com ) suggests that tests utilizing its I-Port... generate results that may indicate mild traumatic...
Other Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 5Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 6Neuro Kinetics: Research Suggests I-Portal(R) NOTC Data Shows Mild Traumatic Brain Injuries That Other Technologies Miss 2Neuro Kinetics: Research Suggests I-Portal(R) NOTC Data Shows Mild Traumatic Brain Injuries That Other Technologies Miss 3
(Date:11/22/2009)... HealthSmart, an innovative healthcare benefit...ccessfully completed a recapitalization with Silve...r lenders. Silver Point Capital, L.P. is a privat... This recapitalization allows the Company to cont...y. , , (PRWEB) November ...
(Date:11/21/2009)...N, Nov. 21 DNC Chairman...e Senate voted to begin full debate of health insu...w.newscom.com/cgi-bin/prnh/20080519/DNCLOGO ) ,...on the road to enacting health insurance reform. B...will now have an opportunity to debate the health ...
(Date:11/21/2009)... November 21, 2009 Test ...Test Test Test Test Test Test Test Test,Test Test ...Test Test Test,Test Test Test Test Test Test Test ... test More test More test More test More test More... test More test More test More,test More test , ,...
(Date:11/21/2009)... New Haven Dental Group merges their practice ... CT. , (PRWEB) November 2...f partners Dr. David Gibson, Dr. Dean Cloutier, Dr... merged their growing practice with that of esteem...ickman decided he wanted to retire from dentistry ...
(Date:11/20/2009)...NGTON, Nov. 20 The Unit... Senate to make essential changes its health refor...ortion funding and conscience protection on aborti...nd include strong provisions for adequate affordab...care bill an "enormous disappointment" that create...
Breaking Medicine News(10 mins):Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:New Haven Dental Group Expands Their Vision 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2
...nd vitamin C reduced blood pressure back to normal...s a pilot study.// "Combinations of garlic a...ontrol of marginally high blood pressure," wrote a...al cell NO production, an effect that was shown to...
... herbal drug could be damaged by overplanting of t...orld Health Organization (WHO) said on Monday. ... be more carefully farmed to meet a growing global...r centuries. It is now widely regarded as the best...
... an eye each allegedly due to medical neglect afte...d the patients// were to blame because they had no...dministration had organised a cataract operation c...who belong to Boden, Gunduri, Khandapal and Latapa...
...on for clinical trials for many pharmaceutical gia...Squibb, GlaxoSmithkline, Eli Lilly are among those... Currently over 226 clinical trials approved...icipants at home, western drug companies are looki...
...'t cause the pain and bruising common with existin...eam in California. In a bid to confront the ... the pain and discomfort experienced by patients, ... drug delivery company StratGent Life Sciences. ...
...Wanganui hospital is reported to have practiced fo...ed sterilization// procedures. While talking o... that Dr. Hasil was having various problems in his...ures last year. The general failure rate in such p...
Other Medicine News:Health News:Garlic Plus Vitamin C may Reduce Blood Pressure 2Health News:Malaria-curing Herb Must Be Carefully Farmed - WHO 2Health News:India Fast Become Prime Location for Clinical Trials, but Vigilance Called for 2Health News:Micro-jets for Painless Needle-free Injections 2Health News:Micro-jets for Painless Needle-free Injections 3
SureStep AMPII/BZO300/COC/MDMA/MOP/THC
SureStep THC/COC/MAMPII
SureStep THC/COC
SureStep Barbiturates (BAR)
Medicine Products: